Skip to content

How a viral video gave a huge boost to new gene therapy

Short Wave

Hosted by Emily Kwong

14m
Transcript

Original podcast

Where to listen

Summary

Written by a model from the transcript; not yet reviewed.

This episode explores the long and winding journey behind the approval of a new gene therapy for San Filippo syndrome, a fatal neurodegenerative condition in children. The guest traces the story of the O'Neill family, who in 2014 launched a viral GoFundMe campaign featuring a video made by a stranger to raise research funds after their daughter Eliza was diagnosed at age four. Over more than a decade, the research weathered funding crises, shifts between biotech companies, and regulatory hurdles before the FDA finally approved the one-time intravenous infusion, now named Feiyuvi. The discussion highlights both the triumph of patient advocacy and scientific persistence and the stark realities of high drug pricing, with the therapy costing nearly four million dollars.

  • Early diagnosis and treatment are critical because neurodegenerative damage cannot be easily reversed once it occurs. 12:27
  • Preclinical research can be sustained by dedicated patient foundations when traditional funding sources dry up. 9:19
  • Viral internet campaigns can break fundraising records and accelerate public awareness for rare disease research. 11:02
  • Gene therapies using modified viral vectors can deliver working copies of broken genes throughout the body. 7:45

Chapters

  1. 0:00
    Capella University Intro

    The episode opens with a Capella University promotional message.

  2. 1:14
    Eliza Diagnosed with San Filippo

    The O'Neill family learns that their daughter Eliza has the rare neurodegenerative disease.

  3. 10:30
    Viral Fundraising Video

    The family creates a viral YouTube video that raises millions for research.

  4. 11:03
    From Viral to Funding

    The viral video leads to record-breaking GoFundMe donations and keeps research alive.

  5. 11:58
    FDA Review and Approval

    The FDA reviews the gene therapy, resubmits, and finally approves Feiyuvi in September 2026.

  6. 13:15
    Cost and Access Challenges

    Discussion of the $4 million price tag for Feiyuvi and its implications for patients and the healthcare system.

Highlights

  • 1:07

    Diagnosed With San Filippo Syndromestory

    At age four, Eliza O'Neill was diagnosed with a rare, fatal neurodegenerative condition called San Filippo syndrome after showing developmental delays.

  • 7:45

    Using Viruses to Deliver Genesinsight

    Researchers developed a gene therapy using a modified cold virus as a vector to deliver working copies of a broken gene into a patient's cells.

  • 8:32

    Moving From Brain Injections to Infusionsstrategy

    Direct injections into mouse brains failed because San Filippo is a whole body disease, so researchers switched to intravenous infusions that cross the blood-brain barrier.

  • 9:46

    Patient Foundations Funded the Researchdata

    When research funds ran low in 2009, eight different patient foundations stepped in to keep the preclinical work alive until human trials could begin.

  • 11:02

    Viral Video Breaks GoFundMe Recordsstory

    A viral video made for free by a stranger helped the O'Neill family break GoFundMe records by raising two million dollars in a few weeks.

  • 13:15

    A Four Million Dollar Price Tagdata

    Ultragenics priced the one-time gene therapy infusion at nearly four million dollars, putting severe strain on the healthcare system and raising questions about access.

Quotes

  • “In the spring of 2014, the Saving Eliza video helped the O'Neills break GoFundMe's record at the time, raising $1 million in just a few weeks.”
    Unnamed speaker · 11:02
  • “The drug Feiyuvi now is available on the market.”
    Emily Kwong · 12:22
  • “Ultragenics set the price at nearly $4 million for the one‑time infusion. And that ties it for the second most expensive gene therapy ever.”
    Unnamed speaker · 13:15
  • “The foundations kept the work going until the research was ready for the first human trial.”
    Unnamed speaker · 10:03
  • Capella University 0:00–0:14
  • Whole Foods Market 3:30–3:58
  • Edward Jones 3:56–4:25
  • Schwab 4:27–4:48
  • Edward Jones 16:30–17:00
  • The Hartford 17:01–17:30

About this episode

Sanfilippo syndrome is a rare and degenerative disease that can be fatal by the time someone reaches their teens. So the O’Neill family knew they didn’t have much time after learning their 4-year old daughter, Eliza, had it. At the time no treatment existed, and the world of drug development had its eyes on more common illnesses. So the family took an all hands on deck, unusual approach to directly raise money and boost medical research. NPR pharmaceutical correspondent Sydney Lupkin shares what happened next, and what she learned from the O’Neills story about the promises https://www.npr.org/2026/11/01/nx-s1-6014739/sanfilippo-gene-therapy-fayuvi and challenges https://www.npr.org/2026/02/24/nx-s1-5723768/gene-therapy-access of drug development. Interested in more medical science? Email us your question at [email protected] mailto:[email protected]. Support public media with NPR+ and enjoy perks for over 25 podcasts like this one. This show’s perks include sponsor-free listening. Learn more at plus.npr.org http://plus.npr.org See pcm.adswizz.com https://pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences. NPR Privacy Policy https://www.npr.org/about-npr/179878450/privacy-policy

Transcript

0:00
14:53

2,737 words · 7 speakers

Speaker names marked are inferred from speaking time and the show’s known hosts — they are not voice-verified.

Topics

  • Ultragenics
  • Feiyuvi
  • ABC News
  • Food and Drug Administration
  • Nationwide Children's Hospital
  • GoFundMe
  • Ben's Dream
  • A Cure for Kirby

Page updated · transcript and summary are machine-generated